Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 281 0850

Website: kodiak.com

Address:

1250 Page Mill Road, Palo Alto, United States

Snackdaddy May. 19 at 2:10 PM

$KOD very well executed sell off. systematic by some big palyer. slowly crashing it to buy back in. I bet you it runs back up the same way unless retail starts to load up. Question is is he bringing it all the way to $25

0 · Reply

Snackdaddy May. 19 at 10:37 AM

$KOD look at the bid. stay far away feom this . someone is taking this all the way down to $25 to buy back in. they are slowly taking tons of profit from the highs. easy short if you want to follow them down. this will be $25 probably by Monday

0 · Reply

biomaster22 May. 18 at 9:20 PM

$KOD wow never thought I see this as a falling knife type of play

2 · Reply

Snackdaddy May. 18 at 5:14 PM

$KOD when the dust settles it will be interesting to see who sold these millions of shares the last two weeks. somebosy wanted out .

0 · Reply

Whiskeyunderthebed May. 18 at 4:56 PM

$KOD this has been getting spanked.

1 · Reply

Snackdaddy May. 18 at 4:13 PM

$KOD wild, no bottom

0 · Reply

Snackdaddy May. 18 at 10:30 AM

$KOD wow still going further red guess we will see that 33.50 which is the low since the late march news

0 · Reply

spinusn27 May. 15 at 9:26 PM

$KOD Sirenia Capital just filed a new 5.7 percent stake in KOD today. That explains the late volume surge. Major funds are building positions ahead of the main clinical results coming in September. Long term thesis is perfectly intact. $KOD

1 · Reply

Snackdaddy May. 15 at 7:46 PM

$KOD watch for a big dump like last Friday with 5-10mins left

0 · Reply

Snackdaddy May. 15 at 7:44 PM

$KOD pattern stays in place a little pump for more dump. in the last week millions of shares have been dumped. Dont be surprised to see a filing on who dumped this

0 · Reply

Kodiak Sciences upgraded to Buy from Neutral at Chardan

2026-05-07T21:46:34.000Z - 11 days ago

Kodiak Sciences reports Q1 EPS (94c), consensus ($1.01)

May 7, 2026, 4:00 PM EDT - 11 days ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

May 7, 2026, 4:00 PM EDT - 11 days ago

Kodiak Sciences Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 11 days ago

Kodiak Sciences Quarterly report: Q1 2026

May 1, 2026, 12:23 AM EDT - 18 days ago

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Apr 22, 2026, 8:00 AM EDT - 27 days ago

Kodiak Sciences Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 27 days ago

Kodiak Sciences Proxy statement: Proxy filing

2026-04-02T16:07:19.000Z - 6 weeks ago

Kodiak Sciences falls -8.7%

2026-04-01T16:27:41.000Z - 6 weeks ago

Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings

2026-04-01T15:15:17.000Z - 6 weeks ago

Kodiak Sciences reports Q4 EPS ($1.05) vs (84c) last year

2026-04-01T14:07:48.000Z - 6 weeks ago

Kodiak Sciences rises 10.7%

Mar 31, 2026, 4:45 PM EDT - 6 weeks ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Mar 31, 2026, 4:00 PM EDT - 6 weeks ago

Kodiak Sciences Annual report: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 6 weeks ago

Kodiak Sciences Earnings release: Q4 2025

2026-03-30T19:20:11.000Z - 7 weeks ago

Kodiak Sciences options imply 7.3% move in share price post-earnings

Mar 30, 2026, 10:00 AM EDT - 7 weeks ago

Kodiak Sciences: Road To $120

2026-03-27T13:29:25.000Z - 7 weeks ago

Kodiak Sciences price target raised to $80 from $50 at UBS

2026-03-27T10:05:12.000Z - 7 weeks ago

Kodiak Sciences price target raised to $58 from $38 at H.C. Wainwright

2026-03-26T18:10:55.000Z - 7 weeks ago

Kodiak Sciences price target raised to $56 from $39 at Jefferies

Mar 26, 2026, 12:33 PM EDT - 7 weeks ago

Kodiak Sciences stock soars over 60%: what's behind the sharp rally

2026-03-26T13:00:50.000Z - 7 weeks ago

Morning Movers: Kodiak Sciences skyrockets following GLOW2 study results

CMC CRBG DBI EQH LOVE MLKN NAVN

Mar 26, 2026, 8:12 AM EDT - 7 weeks ago

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

2026-03-26T12:00:30.000Z - 7 weeks ago

Kodiak Sciences reports GLOW2 study of Zenkuda met primary endpoint

Mar 26, 2026, 6:00 AM EDT - 7 weeks ago

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Mar 12, 2026, 7:00 AM EDT - 2 months ago

Kodiak Sciences Slides: Corporate presentation

Feb 4, 2026, 7:00 AM EST - 3 months ago

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Jan 22, 2026, 10:26 AM EST - 4 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX LITE

2026-01-22T11:11:04.000Z - 4 months ago

Kodiak Sciences price target raised to $38 from $26 at H.C. Wainwright

Jan 12, 2026, 4:30 PM EST - 4 months ago

Kodiak Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 4 months ago

Kodiak Sciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:19 PM EST - 4 months ago

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

2026-01-07T13:20:26.000Z - 4 months ago

Kodiak Sciences assumed with a Buy at UBS

Dec 18, 2025, 8:26 PM EST - 5 months ago

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

2025-12-17T11:11:47.000Z - 5 months ago

Kodiak Sciences 6.956M share Spot Secondary priced at $23.00

Dec 16, 2025, 10:55 PM EST - 5 months ago

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 5 months ago

Kodiak Sciences Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 3:00 PM EST - 5 months ago

Kodiak Sciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 17, 2025, 11:30 AM EST - 6 months ago

Kodiak Sciences Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 11:30 AM EST - 6 months ago

Kodiak Sciences Slides: FY 2025

Nov 13, 2025, 4:05 PM EST - 6 months ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 13, 2025, 4:00 PM EST - 6 months ago

Kodiak Sciences Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 6 months ago

Kodiak Sciences Quarterly report: Q3 2025

Nov 12, 2025, 5:48 PM EST - 6 months ago

Kodiak Sciences to Present at Upcoming Investor Conferences

Nov 5, 2025, 7:00 AM EST - 6 months ago

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

Oct 31, 2025, 12:01 PM EDT - 7 months ago

The Big 3: GOOGL, KOD, FTK

GOOG GOOGL FTK

Sep 15, 2025, 7:00 AM EDT - 8 months ago

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Aug 27, 2025, 10:40 AM EDT - 9 months ago

Harbour BioMed Reports 2025 Interim Results

Aug 19, 2025, 2:18 PM EDT - 9 months ago

Kodiak Sciences to Present at American Chemical Society Fall 2025

Aug 13, 2025, 4:00 PM EDT - 9 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Aug 13, 2025, 4:00 PM EDT - 9 months ago

Kodiak Sciences Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 9 months ago

Kodiak Sciences Earnings release: Q2 2025

Jul 16, 2025, 1:00 PM EDT - 10 months ago

Kodiak Sciences Transcript: R&D Day 2025

Jul 16, 2025, 1:00 PM EDT - 10 months ago

Kodiak Sciences Slides: FY 2025

Jul 10, 2025, 8:00 AM EDT - 11 months ago

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Jun 25, 2025, 4:45 PM EDT - 11 months ago

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

Jun 5, 2025, 9:20 AM EDT - 1 year ago

Kodiak Sciences Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 9:32 PM EDT - 1 year ago

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 22, 2025, 4:00 PM EDT - 1 year ago

Kodiak Sciences Quarterly report: Q1 2025

May 22, 2025, 4:00 PM EDT - 1 year ago

Kodiak Sciences Earnings release: Q1 2025

May 14, 2025, 4:15 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 1, 2025, 11:43 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Kodiak Sciences Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Kodiak Sciences Proxy statement: Proxy Filing

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 10:30 AM EDT - 1 year ago

Kodiak Sciences Annual report: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

Kodiak Sciences Earnings release: Q4 2024

Mar 10, 2025, 4:39 PM EDT - 1 year ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Feb 4, 2025, 7:30 AM EST - 1 year ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

Kodiak Sciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

Kodiak Sciences Slides: FY 2025

Jan 7, 2025, 6:00 AM EST - 1 year ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 2:35 PM EST - 1 year ago

Kodiak Sciences Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 21, 2024, 4:00 AM EST - 1 year ago

Kodiak Sciences Transcript: Jefferies London Healthcare Conference 2024

Nov 14, 2024, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 14, 2024, 4:00 PM EST - 1 year ago

Kodiak Sciences Earnings release: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Kodiak Sciences Quarterly report: Q3 2024

Nov 11, 2024, 6:15 AM EST - 1 year ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 1 year ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 10:30 AM EDT - 1 year ago

Kodiak Sciences Transcript: R&D Day 2024

Sep 23, 2024, 10:30 AM EDT - 1 year ago

Kodiak Sciences Slides: FY 2024

Sep 23, 2024, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

Aug 14, 2024, 4:00 PM EDT - 1 year ago

Kodiak Sciences Quarterly report: Q2 2024

Aug 14, 2024, 4:00 PM EDT - 1 year ago

Kodiak Sciences Earnings release: Q2 2024

Jun 13, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Transcript: Jefferies 2024 Global Healthcare Conference

Jun 6, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Slides: FY 2024

May 29, 2024, 4:36 PM EDT - 2 years ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:15 PM EDT - 2 years ago

Kodiak Sciences Quarterly report: Q1 2024

May 15, 2024, 4:15 PM EDT - 2 years ago

Kodiak Sciences Earnings release: Q1 2024

May 15, 2024, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 2 years ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Proxy statement: Proxy Filing

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Annual report: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Earnings release: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Slides: Q4 2023

Mar 28, 2024, 6:30 AM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 2 years ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 14, 2023, 7:00 AM EST - 2 years ago

Kodiak Sciences Quarterly report: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

Kodiak Sciences Earnings release: Q3 2023

Nov 6, 2023, 5:00 AM EST - 2 years ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 1, 2023, 11:21 PM EDT - 2 years ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Snackdaddy May. 19 at 2:10 PM

0 · Reply

Snackdaddy May. 19 at 10:37 AM

0 · Reply

biomaster22 May. 18 at 9:20 PM

$KOD wow never thought I see this as a falling knife type of play

2 · Reply

Snackdaddy May. 18 at 5:14 PM

$KOD when the dust settles it will be interesting to see who sold these millions of shares the last two weeks. somebosy wanted out .

0 · Reply

Whiskeyunderthebed May. 18 at 4:56 PM

$KOD this has been getting spanked.

1 · Reply

Snackdaddy May. 18 at 4:13 PM

$KOD wild, no bottom

0 · Reply

Snackdaddy May. 18 at 10:30 AM

$KOD wow still going further red guess we will see that 33.50 which is the low since the late march news

0 · Reply

spinusn27 May. 15 at 9:26 PM

1 · Reply

Snackdaddy May. 15 at 7:46 PM

$KOD watch for a big dump like last Friday with 5-10mins left

0 · Reply

Snackdaddy May. 15 at 7:44 PM

$KOD pattern stays in place a little pump for more dump. in the last week millions of shares have been dumped. Dont be surprised to see a filing on who dumped this

0 · Reply

Snackdaddy May. 15 at 7:07 PM

$KOD did somone shake us for good news, or is this a bs pump to unload more shares next week. ?

0 · Reply

Snackdaddy May. 15 at 4:13 PM

$KOD stay clear this is bad. big falling knife. somwbody has been selling steadily since $46 so as not to plummet this to $20Z bad news coming

0 · Reply

Snackdaddy May. 15 at 3:37 PM

$KOD unless this is a shake out for good news then this may be ready to plummet next week to mid $20S

0 · Reply

Snackdaddy May. 15 at 2:31 PM

$KOD look for the 3 month low at this point of 33.5

0 · Reply

Garbageman22 May. 15 at 2:08 PM

$KOD yep yesterday looked like every time we hit daytime low somebody was buying not so much today

0 · Reply

spinusn27 May. 15 at 1:59 PM

$KOD the $34.50 is the line in the sand. Breaking below this is bad.

1 · Reply

Snackdaddy May. 15 at 1:45 PM

$KOD ugly

0 · Reply

Snackdaddy May. 15 at 1:13 PM

$KOD wow, continuing to bleed out $37 now. looks like $35 on deck for Monday. i think someone is slowly unwinding their position. bad news

0 · Reply

Snackdaddy May. 14 at 5:56 PM

$KOD lost a quick 21% in days. looks like people are rotating out of this.

1 · Reply

BB_88_ May. 13 at 1:02 PM

$KOD damn almost shorted 46s and then almost bought yesterday at low. Fuked both up it seems. Will keep on radar

1 · Reply

Stekli27 May. 12 at 5:14 PM

$KOD don’t worry, be happy 🎶

1 · Reply

Snackdaddy May. 12 at 3:49 PM

$KOD wow, cant belive this almost don $10 from last week

0 · Reply

Market Cap	2.32B
Revenue (ttm)	0.00
Net Income (ttm)	-229.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	708,900
Avg Vol	1,178,510
Day's Range	N/A - N/A
Shares Out	62.58M
Stochastic %K	5%
Beta	2.32
Analysts	Strong Sell
Price Target	$62.67